Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | HPGD | P15428 | 5/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | TOP2A | P11388 | 2/20 | 0.46 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | CLK2 | P49760 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9564462 | 0.87 | KCNH2 (0.43) | KCNH2HRH3ALDH1A1KDM4EHPGD | |
| SCHEMBL1915366 | 0.85 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| SCHEMBL30615686 | 0.85 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| Bicarbonate SCHEMBL10873564 | 0.81 | KDM4E (0.66) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| SCHEMBL10655744 | 0.81 | KDM4E (0.47) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| SCHEMBL14585956 | 0.81 | ALDH1A1 (0.48) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| SCHEMBL10945859 | 0.80 | KDM4E (0.48) | HRH3ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL30564229 | 0.79 | ALDH1A1 (0.48) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| SCHEMBL6773934 | 0.79 | KDM4E (0.76) | KCNH2HRH3ALDH1A1KDM4EHPGD | |
| SCHEMBL10947254 | 0.78 | KDM4E (0.44) | ALDH1A1KDM4EHPGDHSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20180179522-A1 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-20180169109-A1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180169109-A1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | NFATC1, GZMB, ICOS | KCNH2 4774/4885HRH3 3509/4885ALDH1A1 4524/4885 |
| US-20180179522-A1 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | PSMG3, MYCBP, DBN1 | KCNH2 4882/4885HRH3 4117/4885ALDH1A1 4528/4885 |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DBN1, MYCBP, PSMG3 | KCNH2 4883/4885HRH3 4186/4885ALDH1A1 4238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.